Patents by Inventor Syed V. S. Kashmiri
Syed V. S. Kashmiri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8835167Abstract: The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody.Type: GrantFiled: August 23, 2013Date of Patent: September 16, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Syed V. S. Kashmiri, Jeffrey Schlom, Eduardo A. Padlan
-
Publication number: 20130337559Abstract: The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody.Type: ApplicationFiled: August 23, 2013Publication date: December 19, 2013Applicant: The Govt. of the U.S.A. as represented by the Secretary of the Dept. of Health & Human ServicesInventors: Syed V.S. Kashmiri, Jeffrey Schlom, Eduardo Padlan
-
Patent number: 8535890Abstract: The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody.Type: GrantFiled: March 2, 2011Date of Patent: September 17, 2013Assignee: The United of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Syed V. S. Kashmiri, Jeffrey Schlom, Eduardo A. Padlan
-
Patent number: 8029788Abstract: The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.Type: GrantFiled: June 21, 2010Date of Patent: October 4, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Syed V S Kashmiri, Eduardo A. Padlan, Jeffrey Schlom
-
Publication number: 20110159525Abstract: The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody.Type: ApplicationFiled: March 2, 2011Publication date: June 30, 2011Inventors: Syed V.S. Kashmiri, Jeffrey Schlom, Eduardo A. Padlan
-
Patent number: 7919607Abstract: The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.Type: GrantFiled: May 28, 2009Date of Patent: April 5, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Syed V. S. Kashmiri, Jeffrey Schlom, Eduardo A. Padlan
-
Patent number: 7915396Abstract: Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 from humanized antibody HuCC49V10. The L-CDR1, L-CDR2, L-CDR3 are within a HuCC49V10 light chain framework region that includes the corresponding amino acid from LEN at position 5, 19, 21, and 106 in the light chain. The H-CDR1, H-CDR2, and H-CDR3 are within a heavy chain HuCC49V10 framework comprising a human 21/28? CL residue at positions 20, 38, 48, 66, 67, 69, and 80 in the heavy chain. These humanized CC49 antibodies retain binding affinity for TAG-72 and have reduced immunogenicity, as compared to a parental HuCC49V10 antibody. Methods are disclosed herein for using these antibodies in the treatment or diagnosis of a tumor, such as a carcinoma, expressing TAG-72.Type: GrantFiled: August 20, 2009Date of Patent: March 29, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Syed V. S. Kashmiri, Jeffrey Schlom, Eduardo A. Padlan
-
Publication number: 20100303720Abstract: The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.Type: ApplicationFiled: June 21, 2010Publication date: December 2, 2010Inventors: Syed V.S. Kashmiri, Eduardo A. Padlan, Jeffrey Schlom
-
Patent number: 7763719Abstract: The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.Type: GrantFiled: July 11, 2007Date of Patent: July 27, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Syed V S. Kashmiri, Eduardo A. Padlan, Jeffrey Schlom
-
Publication number: 20090317903Abstract: The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.Type: ApplicationFiled: May 28, 2009Publication date: December 24, 2009Inventors: Syed V.S. Kashmiri, Jeffrey Schlom, Eduardo A. Padlan
-
Publication number: 20090311780Abstract: Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 from humanized antibody HuCC49V10. The L-CDR1, L-CDR2, L-CDR3 are within a HuCC49V10 light chain framework region that includes the corresponding amino acid from LEN at position 5, 19, 21, and 106 in the light chain. The H-CDR1, H-CDR2, and H-CDR3 are within a heavy chain HuCC49V10 framework comprising a human 21/28? CL residue at positions 20, 38, 48, 66, 67, 69, and 80 in the heavy chain. These humanized CC49 antibodies retain binding affinity for TAG-72 and have reduced immunogenicity, as compared to a parental HuCC49V10 antibody. Methods are disclosed herein for using these antibodies in the treatment or diagnosis of a tumor, such as a carcinoma, expressing TAG-72.Type: ApplicationFiled: August 20, 2009Publication date: December 17, 2009Inventors: Syed V.S. Kashmiri, Jeffrey Schlom, Eduardo A. Padlan
-
Patent number: 7589181Abstract: Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 from humanized antibody HuCC49V10. The L-CDR1, L-CDR2, L-CDR3 are within a HuCC49V10 light chain framework region that includes the corresponding amino acid from LEN at position 5, 19, 21, and 106 in the light chain. The H-CDR1, H-CDR2, and H-CDR3 are within a heavy chain HuCC49V10 framework comprising a human 21/28? CL residue at positions 20, 38, 48, 66, 67, 69, and 80 in the heavy chain. These humanized CC49 antibodies retain binding affinity for TAG-72 and have reduced immunogenicity, as compared to a parental HuCC49V10 antibody. Methods are disclosed herein for using these antibodies in the treatment or diagnosis of a tumor, such as a carcinoma, expressing TAG-72.Type: GrantFiled: August 27, 2004Date of Patent: September 15, 2009Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Syed V. S. Kashmiri, Jeffrey Schlom, Eduardo A. Padlan
-
Patent number: 7569673Abstract: The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.Type: GrantFiled: June 26, 2003Date of Patent: August 4, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Syed V. S. Kashmiri, Jeffrey Schlom, Eduardo A. Padlan
-
Patent number: 7256004Abstract: The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.Type: GrantFiled: August 25, 2004Date of Patent: August 14, 2007Assignee: United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Syed V. S. Kashmiri, Eduardo A. Padlan, Jeffrey Schlom
-
Patent number: 7179899Abstract: Novel composite and humanized anti-TAG-72 monoclonal antibodies, antibody fragments, and derivatives thereof using human subgroup IV kappa light chain framework regions.Type: GrantFiled: September 25, 2002Date of Patent: February 20, 2007Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Peter S. Mezes, Ruth A. Richard, Kimberly S. Johnson, Jeffrey Schlom, Syed V. S. Kashmiri, Liming Shu, Eduardo A. Padlan
-
Patent number: 6818749Abstract: The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.Type: GrantFiled: April 30, 2001Date of Patent: November 16, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Syed V. S. Kashmiri, Eduardo A. Padlan, Jeffrey Schlom
-
Publication number: 20030165498Abstract: Novel composite and humanized anti-TAG-72 monoclonal antibodies, antibody fragments, and derivatives thereof using human subgroup IV kappa light chain framework regions.Type: ApplicationFiled: September 25, 2002Publication date: September 4, 2003Inventors: Peter S. Mezes, Ruth A. Richard, Kimberly S. Johnson, Jeffrey Schlom, Syed V.S. Kashmiri, Liming Shu, Eduardo A. Padlan
-
Patent number: 6495137Abstract: Novel composite and humanized anti-TAG-72 monoclonal antibodies, antibody fragments, and derivatives thereof using human subgroup IV kappa light chain framework regions.Type: GrantFiled: October 30, 1997Date of Patent: December 17, 2002Assignee: The Dow Chemical CompanyInventors: Peter S. Mezes, Ruth A. Richard, Kimberly S. Johnson, Jeffrey Schlom, Syed V. S. Kashmiri, Liming Shu, Eduardo A. Padlan
-
Patent number: 5892019Abstract: Construction of a single gene encoding a signal-chain immunoglobulin-like molecule is described. This single-gene approach circumvents inefficiencies inherent in delivering two genes into a mammalian cell and in the assembly of a functional immunoglobulin molecule. It also facilitates ex vivo transfection of cells for gene-therapy protocols. The single-chain protein comprises the heavy- and light-chain variable (V.sub.H and V.sub.L) domains of a monoclonal antibody covalently joined through a short linker peptide, while the carboxyl end of a V domain is linked to the amino terminus of a human constant region such as .gamma.1 Fc, through the hinge region. The single-chain protein assembles into a dimeric molecule of .apprxeq.120 kDa and is secreted into the culture fluid. The single-chain immunoglobulin-like protein shows similar antigen binding affinity to that of chimeric or parental antibody and mediates ADCC.Type: GrantFiled: September 1, 1994Date of Patent: April 6, 1999Assignee: The United States of America, as represented by The Department of Health and Human ServicesInventors: Jeffrey Schlom, Syed V. S. Kashmiri, Liming Shu